enow.com Web Search

  1. Ads

    related to: treatment options for acute lymphoblastic leukemia

Search results

  1. Results from the WOW.Com Content Network
  2. Acute lymphoblastic leukemia - Wikipedia

    en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia

    Brexucabtagene autoleucel (Tecartus) was approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in October 2021. [ 71 ] [ 72 ] Each dose of brexucabtagene autoleucel is a customized treatment created using the recipient's own immune system to help fight the lymphoma. [ 73 ]

  3. Obecabtagene autoleucel - Wikipedia

    en.wikipedia.org/wiki/Obecabtagene_autoleucel

    Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. [1] [2] It is a CD19-directed genetically modified autologous T-cell immunotherapy.

  4. T-cell acute lymphoblastic leukemia - Wikipedia

    en.wikipedia.org/wiki/T-cell_acute_lymphoblastic...

    Currently, standard treatment for T-cell acute lymphoblastic leukemia (T-ALL) involves long-term chemotherapy and medication to prevent or treat side effects associated with low white blood cell counts resulting from intensive chemotherapy regimens. The treatment typically occurs in three stages: induction, consolidation, and maintenance. [3]

  5. Leukemia - Wikipedia

    en.wikipedia.org/wiki/Leukemia

    In 2011, a year after treatment, two of the three people with advanced chronic lymphocytic leukemia were reported to be cancer-free [99] and in 2013, three of five subjects who had acute lymphocytic leukemia were reported to be in remission for five months to two years. [100]

  6. Asparaginase - Wikipedia

    en.wikipedia.org/wiki/Asparaginase

    In June 2021, the FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in people aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase.

  7. Acute lymphoblastic leukemia (ALL) 4.0% Acute myeloid leukemia (AML) 8.7% Chronic lymphocytic leukemia (CLL) sorted under lymphomas according to current WHO classification; called small lymphocytic lymphoma (SLL) when leukemic cells are absent. 10.2% Chronic myelogenous leukemia (CML) 3.7% Acute monocytic leukemia (AMoL) 0.7% Other leukemias 3.1%

  1. Ads

    related to: treatment options for acute lymphoblastic leukemia